Mobile Clinics Cut Deaths by 71 Percent Among People Who Inject Drugs

A clinic on wheels, bringing HIV prevention and addiction treatment together in one place, helped keep people alive. In a clinical trial funded by the National Institutes of Health, adults who received integrated services from a mobile medical unit died at far lower rates than adults who were connected to the same services in the community. Deaths from all causes were 71% lower in the mobile unit group. That mortality result was a secondary outcome of the trial, and the study's primary measures, the actual use of HIV prevention medication and addiction treatment medication, did not differ between the two groups. Both halves of that sentence matter, and this briefing carries both.

What the trial did

The study, known as HPTN 094, enrolled 409 adults in five cities: Houston, Los Angeles, New York City, Philadelphia, and Washington, DC. Every participant injected drugs, lived with opioid use disorder, did not have HIV, and was not taking medication for opioid use disorder when the study began. Each person was willing to consider that treatment.

Participants were randomly assigned to one of two groups. One group received peer navigation together with integrated services delivered on a mobile medical unit for 26 weeks. Peer navigation means support from trained guides who help a person reach care, keep appointments, and stay connected to services. The mobile unit carried PrEP, the medication that prevents HIV infection, medication for opioid use disorder, and a range of supporting clinical services, all in one vehicle that went to where participants already were. The other half received peer navigation alone, with navigators linking them to services available in the community.

What it found

The clearest result was survival. Deaths from all causes were 71% lower among participants who received the integrated mobile services than among those referred to community services. For a population that faces unstable housing, stigma, and fragmented care, that difference is large. One limit belongs on the record: the 71% is a relative reduction, and the NIH release does not publish the raw number of deaths in each group, so the absolute size of the difference cannot be stated from the published material.

There was also movement on treatment itself. No participant was taking medication for opioid use disorder when the study began. By the later study visits, 14% were taking it, a level the researchers describe as clinically meaningful for this population.

Dr. Nora D. Volkow, Director of the National Institute on Drug Abuse, which funded the study, put the problem plainly: "Injection drug use is an important contributor to HIV in the U. S. that also increases risk for other serious infectious diseases. Although we have effective interventions for this population, there are significant barriers to their accessibility and use. Nonetheless, these findings suggest that delivering low threshold services through mobile units could save lives."

What it did not find

The trial's primary measures did not move. Verified use of PrEP was low in both groups, and use of medication for opioid use disorder did not differ between the mobile group and the community group. Dr. Nabila El-Bassel, the Willma and Albert Musher Professor of Social Work at Columbia University and one of the two leaders of the study, explained why the model still matters: "People who inject drugs often face fragmented systems, unstable housing, stigma, and other barriers that make sustained care difficult. Our findings show why we must continue developing models that meet people where they are and connect HIV prevention, addiction treatment, and supportive care in ways that are accessible and responsive to their lives."

The results also have a clear boundary. They speak only to adults who do not have HIV, who inject drugs, and who were willing to consider addiction treatment. They say nothing about people already living with HIV, who need treatment models of their own.

The researchers are direct about the open questions. Low uptake of daily oral PrEP, even with structured peer navigation, points to the importance of testing long acting PrEP options for this population. And because the mortality result was a secondary outcome, the team states that replication is needed before the model can be treated as settled science. The trial was conducted by the HIV Prevention Trials Network, sponsored by the National Institute of Allergy and Infectious Diseases, and the results are published in JAMA Psychiatry.

What it means for the American healthcare ecosystem

The lesson of this trial is not a vehicle. It is an arrangement of care. Prevention, addiction treatment, and personal guidance arrived together, at street level, without asking a person in crisis to cross a fragmented system alone. One of the five test cities was Houston, so this evidence was produced in conditions our own providers and hospitals work in every day.

For providers, the implication is direct. Integration can be treated as the standard rather than the exception, with HIV prevention and addiction care planned as one service, carried by peer navigation. For payers and public agencies, mobile delivery earns a serious place as a channel for the people that buildings do not reach. Both should hold the honest limit in view: a model that saved lives in a trial still has to prove it can raise treatment uptake, and it still has to be tested again.

The measure of this story is simple. When care went to the people who needed it most, fewer of them died.

Sources and Editorial References

National Institutes of Health, news release, "Integrated health service delivery through medical mobile units helped to reduce deaths among individuals at risk for HIV who also inject drugs," November 4, 2026. https://www.nih.gov/news-events/news-releases/integrated-health-service-delivery-through-medical-mobile-units-helped-reduce-deaths-among-individuals-risk-hiv-who-also-inject-drugs

Shoptaw S, El-Bassel N, et al. Mobile Units for Integrated Addiction and Prevention Services for People Who Inject Drugs: The HPTN 094 Randomized Clinical Trial. JAMA Psychiatry, 2026. DOI: 10.1001/jamapsychiatry.2026.3644

Editorial Disclosure

This briefing is based on the National Institutes of Health news release and the published report of the HPTN 094 trial in JAMA Psychiatry. All figures are as reported by NIH and the study investigators. The American Chamber of Health did not independently verify the trial data, and the mortality finding is reported as a secondary outcome of the trial, as the investigators themselves present it.